DRUG THERAPY OF LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Kharkiv National Medical University, Ukraine
This paper analyzes the changes in drug therapy of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) over the recent five years. Currently, drug therapy strategy is based not only on correction of LUTS, hematuria or complications of BPH (urinary tract infection), but also on preventing disease progression. Tamsulosin is a selective blocker of the main alfa−1A−adrenergic receptors. New drugs, including Silodosin and Naftopidil have been introduced into clinical practice. Type 5 phosphodiesterase inhibitors also demonstrated high efficiency in correction both obstructive and irritation symptoms. It has been objectively established that type 5 phosphodiesterase inhibitors inhibitors did not affect the volume rate of urination. Currently, among the three drugs in this group (Sildenafil, Vardenafilum, Tadalafilun), only Tadalafilum 5 mg once a day has been officially licensed for treatment of male LUTS with or without erectile dysfunction. Sufficient amount of information about the long−term use of type 5 phosphodiesterase inhibitors, their influence on the size of the prostate and BPH progression has not been accumulated yet. As to the new areas of medical treatment of LUTS/BPH, the role of vitamin D receptor agonists and antagonists of growth hormone were described, as well as the results of the use of new types of combination therapy (Tadalafilum + 5A reductase inhibitors) were discussed.
Key words: lower urinary tract signs, benign prostatic hyperplasia, adrenoblockers, phosphodiesterase type 5 inhibitor, combination therapy.